Although these studies separately showed elevated expressions of CD38 and NGAL-R, it is very likely that both antigens are co-expressed in these tumors, and therefore suggest that a combination of anti-CD38/NGAL-R Abs may offer new therapeutic options for the management of these cancers. The gene discussed is CD38; the disease is cancer.